Halliburton Company vs Sana Biotechnology Inc — how do they compare? Halliburton Company trades at $33.52 (market cap $28.16B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Halliburton Company is far larger — about 24.9× Sana Biotechnology Inc's market cap, and Halliburton Company pays a 2.01% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HAL | SANA | |
|---|---|---|
Market Cap | $28.16B | $1.13B |
Sector | Energy | Health |
52-Week High | $42.98 | $5.92 |
52-Week Low | $20.97 | $2.68 |
Enterprise Value | $34.31B | $1.05B |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $33.64, up 5.49% on the day, with a bullish technical signal despite a near-term overbought RSI. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent contract wins in international markets, such as with Kuwait Oil Company and Beetaloo Energy, highlight growth initiatives, though net income declined in 2025. The stock's valuation appears reasonable with a P/E of 17.7 and P/S of 1.27.
The outlook is supported by strong analyst sentiment with a $43.60 price target, but risks include geopolitical tensions impacting Middle East operations and a softer oilfield services market. Earnings growth from international expansion is the key catalyst, while margin pressure and debt levels warrant monitoring for sustained shareholder value.
No Aura AI signal available yet.
Trailing returns across standard periods
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →